Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
Crossref DOI link: https://doi.org/10.1007/s11912-021-01128-5
Published Online: 2021-11-09
Published Print: 2021-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lainé, Alexandra http://orcid.org/0000-0002-8367-6115
Sims, Travis T.
Le Saux, Olivia
Ray-Coquard, Isabelle
Coleman, Robert L.
Text and Data Mining valid from 2021-11-09
Version of Record valid from 2021-11-09
Article History
Accepted: 19 August 2021
First Online: 9 November 2021